Trade Wars And Geopolitical Conflict: Navigating US Tariff Changes And The War In Iran

By Dan Bell

The pharmaceutical industry is navigating one of the most volatile trade environments in modern history. What began as a wave of tariff-driven policy changes and geopolitical realignment has evolved into a broader restructuring of global supply chains, manufacturing strategies and cross-border logistics. Since 2025, pharmaceutical companies have faced mounting pressure to reassess where products are sourced, manufactured and distributed, while simultaneously adapting to shifting U.S. trade policies, evolving international alliances and growing operational uncertainty.

Major investments in U.S.-based manufacturing and research have been announced in response to tariff negotiations, even as legal challenges and Supreme Court rulings continue to reshape the regulatory landscape. At the same time, global disruptions — from changing trade agreements to escalating conflict in the Gulf region — are increasing transportation costs and complicating the movement of time- and temperature-sensitive medicines. In this rapidly changing environment, pharmaceutical organizations are being forced to rethink risk management, supply chain resilience and long-term continuity planning on a global scale.